Lung Cancer Surgery

Global Lung Cancer Surgery Market to Reach US$1.6 Billion by 2032

The global market for Lung Cancer Surgery estimated at US$1.2 Billion in the year 2025, is expected to reach US$1.6 Billion by 2032, growing at a CAGR of 4.4% over the analysis period 2025-2032. Thoracoscopes Product Type, one of the segments analyzed in the report, is expected to record a 3.8% CAGR and reach US$437.3 Million by the end of the analysis period. Growth in the Mediastinoscopes Product Type segment is estimated at 5.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$377.1 Million While China is Forecast to Grow at 7.9% CAGR

The Lung Cancer Surgery market in the U.S. is estimated at US$377.1 Million in the year 2025. China, the world`s second largest economy, is forecast to reach a projected market size of US$396.6 Million by the year 2032 trailing a CAGR of 7.9% over the analysis period 2025-2032. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.2% and 3.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.9% CAGR.

Global Lung Cancer Surgery Market - Key Trends & Drivers Summarized

Why Is Lung Cancer Surgery a Critical Component of Cancer Treatment Today?

Lung cancer remains one of the most prevalent and deadly cancers worldwide, making effective treatment modalities like surgery crucial in the fight against this disease. Surgery for lung cancer involves the removal of the tumor and surrounding lung tissue where cancer cells may have spread. This approach is generally most effective in the early stages of lung cancer, specifically non-small cell lung cancer (NSCLC), where the tumor is localized and operable. Advances in surgical techniques, including minimally invasive procedures such as video-assisted thoracic surgery (VATS) and robot-assisted surgery, have significantly improved outcomes for patients. These techniques reduce surgical trauma and recovery time, decrease the risk of complications, and can improve the quality of life post-surgery compared to traditional open surgery. As detection methods improve and more lung cancers are diagnosed at an operable stage, the role of surgery in treatment regimens continues to expand.

How Are Technological Advances Transforming Lung Cancer Surgery?

The landscape of lung cancer surgery has been transformed by technological advancements that allow for more precise and less invasive procedures. Innovations such as robotic surgery provide surgeons with enhanced dexterity and control, enabling them to perform complex dissections and remove tumors with high precision while preserving healthy tissue. Furthermore, intraoperative imaging technologies like real-time CT scans and fluorescence imaging have improved the accuracy of tumor localization and the assessment of resection margins, ensuring that more of the cancerous tissue is removed during the initial surgery. These advancements not only increase the success rate of surgical interventions but also minimize the physical impact on patients, leading to faster recovery times and less postoperative discomfort.

What Impact Do Early Detection and Personalized Treatment Have on Lung Cancer Surgery Outcomes?

Early detection and personalized treatment approaches are significantly influencing outcomes in lung cancer surgery. The development of low-dose CT screening for high-risk individuals has led to earlier diagnosis of lung cancer, often at a stage when surgical resection is possible and more likely to be curative. Personalized medicine, which involves genetic profiling of tumors to understand their unique characteristics, has also made strides in determining which patients are good candidates for surgery and how they might best respond to additional treatments such as chemotherapy or targeted therapy. This tailored approach helps in strategizing treatment plans that maximize the efficacy of surgery and minimize unnecessary treatments, thereby improving overall patient survival and quality of life.

Growth in the Lung Cancer Surgery Market Is Driven by Several Factors

The growth in the lung cancer surgery market is driven by several factors, encompassing technological advancements, improved detection methods, and an increased emphasis on personalized medicine. Technological innovations in surgical techniques, including minimally invasive and robotic-assisted surgeries, have broadened the range of operable cases and improved patient outcomes, making surgery a more viable option for many patients. Enhanced screening programs have also played a critical role, as they increase the number of early-stage cancers identified, where surgical intervention can be most beneficial. Additionally, as understanding of the genetic basis of lung cancer improves, personalized surgical treatments are becoming more prevalent, allowing for more targeted and effective interventions. These developments, combined with a growing awareness of lung cancer risks and prevention, continue to drive the demand for surgical solutions in the treatment of lung cancer, reflecting a dynamic and evolving marketplace.

SCOPE OF STUDY:

The report analyzes the Lung Cancer Surgery market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Procedure (Thoracotomy, Minimally Invasive Surgery); Device (Surgical Instruments, Monitoring & Visualizing Systems, Endosurgical Equipment)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

SELECT PLAYERS -

• Abbott Molecular, Inc.
• AbbVie, Inc.
• Accuray, Inc.
• Ackermann Instrumente GmbH
• AngioDynamics, Inc.
• Baxter International, Inc.
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Company
• Celgene Corporation
• Daiichi Sankyo Co., Ltd.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher. Show more